Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.

Date publication

janvier 2011

Journal

Clinics and research in hepatology and gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier

Tous les auteurs :
Samalin E, Afchain P, Thézenas S, Abbas F, Romano O, Guimbaud R, Bécouarn Y, Desseigne F, Edeline J, Mitry E, Bouché O, Adenis A, Aparicio T, Dorval E, Kramar A, Ychou M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/21634054

Résumé

The most commonly used schedules are 5-FU in combination with CDDP with or without epirubicin (ECF) or docetaxel (TCF) in treatment of MGA patients (pts), independently of HER status. We evaluated the efficacy of FOLFIRI regimen in a large retrospective series of MGA pts.

Mots clés

Adenocarcinoma, drug therapy, Adult, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic, administration & dosage, Antineoplastic Agents, Phytogenic, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Camptothecin, administration & dosage, Esophageal Neoplasms, drug therapy, Esophagogastric Junction, Female, Fluorouracil, administration & dosage, Humans, Male, Middle Aged, Retrospective Studies, Stomach Neoplasms, drug therapy

Référence

Clin Res Hepatol Gastroenterol. 2011 Jan;35(1):48-54